Bioidentical Hormone Pellets | BHRT Therapy in Portland & Lake Oswego

Bioidentical Hormone Pellets: A Complete Guide to BHRT in Portland & Lake Oswego

Introduction to Bioidentical Hormone Pellets

Bioidentical hormone pellets have been used since the 1930s as one of the earliest and most effective forms of Bioidentical Hormone Replacement Therapy (BHRT). Despite decades of research and clinical use, many patients and even physicians remain unfamiliar with this treatment option. One reason is the limited FDA approval for hormone pellets in women (Testopel® is FDA-approved for men), combined with the pharmaceutical industry’s focus on promoting synthetic hormone products.

However, bioidentical hormone pellets continue to gain popularity because many patients find them to be one of the most convenient and effective ways to achieve hormone balance, requiring insertion only 2–3 times per year.

What Are Bioidentical Hormone Pellets?

Bioidentical hormone pellets are small, solid cylinders made from either estradiol or testosterone that are inserted under the skin. About the size of a Tic Tac, these pellets are typically compounded by specialized pharmacists and delivered in sterile vials for precise dosing and safety.

Benefits of Bioidentical Hormone Pellets

1. Steady Hormone Levels

Unlike creams, pills, or patches that can cause hormonal fluctuations, pellets deliver a consistent release of hormones over several months, helping to avoid mood swings or symptom variability.

2. Bone and Heart Health Support

Studies have shown that estradiol and testosterone pellets may help maintain bone density and support cardiovascular health by positively affecting cholesterol levels and vascular function.

3. Symptom Relief for Men and Women

In women, hormone pellets have been associated with improvements in:

Menopausal symptoms (hot flashes, night sweats, insomnia)
Migraines and menstrual headaches
Sexual wellness concerns such as low libido and vaginal discomfort
Cognitive symptoms like fatigue, depression, and brain fog

Men receiving testosterone pellets often report enhanced energy, strength, mood, and sexual function.

Bioidentical Hormone Pellets and Breast Cancer Risk

Multiple studies, including an 18-year study from the Netherlands, suggest no significant increase in breast cancer risk with hormone pellets. Some research even indicates testosterone may counteract certain risks associated with traditional hormone replacement therapy.

However, because studies have involved small sample sizes, patients should discuss individual risk factors with a qualified hormone therapy provider.

Pellet Insertion: What to Expect

Pellets are inserted under the skin in the upper buttock or hip area using local anesthesia. The in-office procedure takes just a few minutes, with most patients resuming normal activity after 48 hours (avoiding strenuous exercise).

How Long Do Bioidentical Hormone Pellets Last?

Women: Typically 3–5 months
Men: Typically 4–6 months
Pellets dissolve naturally—no removal procedure is required.

Side Effects and Considerations

Possible side effects may include mild bruising, temporary breast tenderness, or acne with higher testosterone doses. Complications are rare when performed by experienced practitioners following proper post-procedure care.

Why Many Doctors Don’t Mention Pellets

Pellets are not patented and are less commercially marketed in the U.S., so many conventional practitioners have limited exposure to the supporting research. However, hormone pellet therapy is widely used in Europe and Australia, with decades of clinical data supporting its safety and effectiveness.

Hormone Therapy for Men

Testosterone levels naturally decline in men starting in their 30s. Men experiencing fatigue, low libido, mood changes, or bone loss should consider testosterone testing and discuss whether bioidentical hormone therapy may help restore optimal levels.

Choosing the Right BHRT Provider in Portland & Lake Oswego

Hormone therapy is highly individualized. Dr. Kathryn Retzler and HormoneSynergy® Clinic specialize in personalized bioidentical hormone replacement therapy with over 24 years of experience optimizing hormone health for men and women in Portland and Lake Oswego.

Conclusion: Is BHRT with Pellets Right for You?

Bioidentical hormone pellets offer a convenient, effective option for hormone replacement therapy with decades of research and patient success stories behind them. Like any medical treatment, they come with benefits and risks, so it’s essential to work with an experienced provider to determine the best approach for your health needs.

i Vest S, Howard J. Clinical experiments with androgens. JAMA.1939;113(21):1869-1872.

ii Gambrell RD, Natrajan PK. Moderate dosage estrogen-androgen therapy improves continuation rates in postmenopausal women: impact of the WHI reports. Climacteric. 2006;9:224-233.

iii Khastgir G, Studd J. Patient‘s outlook, experience, and satisfaction with hysterectomy, bilateral oophorectomy, and subsequent continuation of hormone replacement therapy. Am J Obstet Gynecol. 2000;183(6):1427-33.

iv Handelsman DJ, Mackey MA, Howe C, et al. An analysis of testosterone implants for androgen replacement therapy. Clin Endocrinol (Oxf).1997;47:311-6.

v Jockenhovel F, Vogel E, Kreutzer M, et al. Pharmacokinetics and pharmacodynamics of subcutaneous testosterone implants in hypogonadal men. Clin Endocrinol (Oxf). 1996;45;61-71.

vi Anderson C, Raju K, Forling M, Wheeler M. The effects of surgical menopause and parenteral hormone replacement therapy on bone density, menopausal symptoms, and hormone profiles. Maturitas. 1997;27(suppl 1):70.

vii Barlow DH, Abdalla HI, Roberts DG, et al. Long-term hormone implant therapy – hormonal and clinical effects. Obstet Gynecol. 1986; 67:321.

viii Davis S, McCloud P, Strauss B, et al. Testosterone enhances estradiol‘s effects on postmenopausal bone density and sexuality. Maturitas. 1995;227-236.

ix Garnett T, Studd J, Watson N, et al. The effects of plasma estradiol levels on increases in vertebral and femoral bone density following therapy with estradiol and estradiol with testosterone implants. Obstet Gynecol.1992;79:968-72.

x Garnett T, Studd J, Watson N, et al. A cross-sectional study of the effects of long-term percutaneous hormone replacement therapy on bone density. Obstet Gynecol 1991;78:1002-1007.

xi Holland EF, Leather AT, Studd JW. The effect of 25-mg percutaneous estradiol implants on the bone mass of postmenopausal women. Obstet Gynecol. 1994;83:43-6.

xii Khastgir G, Studd J, Holland N. Anabolic effect of estrogen replacement on bone in postmenopausal women with osteoporosis: histomorphometric evidence in a longitudinal study. J Clin Endocrinol Metab. 2001;86:289-295.

xiii Notelovitz M, Johnston M, Smith S, et al. Metabolic and hormonal effects of 25-mg and 50-mg 17 beta-estradiol implants in surgically menopausal women. Obstet Gynecol. 1987;70:749.

xiv Naessen T. Maintained bone density at advanced ages after long term treatment with low dose oestradiol implants. Br J Obstet Gynecol. 1993;100:454-459.

xv Notelovitz M. Androgen effects on bone and muscle. Fertil Steril.2002;77(Suppl 4):S34-41.

xvi Pereda C, Hannon R, Naylor K, et al. The impact of subcutaneous oestradiol implants on biochemical markers of bone turnover and bone mineral density in postmenopausal women. Br J Obstet Gynecol. 2002;109:812-820.

xviiSavvas M, Studd J, Fogelman I, et al. Skeletal effects of oral oestrogen compared with subcutaneous oestrogen and testosterone in postmenopausal women. BMJ. 1988;297:331-333.

xviii Savvas M, Studd J, Norman S, et al. Increase in bone mass after one year of percutaneous oestradiol and testosterone implants in post-menopausal women who have previously received long-term oral estrogens. Br J Obstet Gynecol. 1992;99:757-760.

xix Studd JW. The dose response of per-cutaneous oestradiol implants on the skeletons of postmenopausal women. Br J Obstet Gynecol. 1994;101:787-791.

xx Vedi S, Purdie W, Ballard P, et al. Bone remodeling and structure in postmenopausal women treated with long-term, high-dose estrogen therapy. Osteoporosis Int. 1999;10:52-58.